Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients-Reference-Cited by-同舟云学术

Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients

Published:2009-07-07 Issue:10 Volume:104 Page:2449-2457
ISSN:0002-9270
Container-title:The American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Buster Erik H C J,Flink Hajo J,Simsek Halis,Heathcote E Jenny,Sharmila Sachithanandan,Kitis George E,Gerken Guido,Buti Maria,de Vries Richard A,Verhey Elke,Hansen Bettina E,Janssen Harry L A

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg2009371.pdf

Reference28 articles.

1. Fattovich G, Bortolotti F, Donato F . Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–352.

2. Lavanchy D . Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97–107.

3. Poland GA, Jacobson RM . Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004;351:2832–2838.

4. Papatheodoridis GV, Manolakopoulos S, Dusheiko G et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:167–178.

5. Krogsgaard K . The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998;5:389–397.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of early hepatitis B virus viral suppression on treatment response in entecavir‐treated hepatitis B e antigen‐positive chronic hepatitis B;Advances in Digestive Medicine;2023-04-12

2. The efficacy and safety of adding on or switching to peginterferon α‐2b in HBeAg‐positive chronic hepatitis B patients with long‐term entecavir treatment: a multicentre randomised controlled trial;Alimentary Pharmacology & Therapeutics;2022-09-20

3. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT;Clinical Gastroenterology and Hepatology;2022-02

4. HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation;Biomedicines;2021-09-29

5. The effects of nucleoside/nucleotide analogues on host immune cells: the baseline for future immune therapy for HBV?;Antiviral Therapy;2020